Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.2500
- TODAY'S CHANGE (%)0.0700 (2.2013%)
- Bid / Lots3.2200/ 12
- Ask / Lots3.2500/ 13
- Open / Previous Close3.2000 / 3.1800
- Day Range
- 52 Week Range
- Volume180,491
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 6918 | 3.24 |
| 09:34 ET | 200 | 3.25 |
| 09:36 ET | 1200 | 3.31 |
| 09:38 ET | 600 | 3.36 |
| 09:39 ET | 600 | 3.36 |
| 09:41 ET | 2470 | 3.42 |
| 09:43 ET | 3690 | 3.35 |
| 09:45 ET | 7687 | 3.37 |
| 09:48 ET | 759 | 3.36 |
| 09:50 ET | 1504 | 3.35 |
| 09:52 ET | 600 | 3.33 |
| 09:54 ET | 535 | 3.32 |
| 09:56 ET | 100 | 3.31 |
| 09:57 ET | 100 | 3.32 |
| 09:59 ET | 1069 | 3.33 |
| 10:03 ET | 430 | 3.3497 |
| 10:06 ET | 1058 | 3.37 |
| 10:08 ET | 392 | 3.37 |
| 10:10 ET | 11525 | 3.33 |
| 10:12 ET | 200 | 3.3 |
| 10:14 ET | 100 | 3.3 |
| 10:15 ET | 598 | 3.31 |
| 10:17 ET | 359 | 3.32 |
| 10:21 ET | 200 | 3.33 |
| 10:24 ET | 550 | 3.325 |
| 10:26 ET | 668 | 3.32 |
| 10:28 ET | 1420 | 3.3371 |
| 10:30 ET | 244 | 3.34 |
| 10:32 ET | 1284 | 3.341 |
| 10:33 ET | 200 | 3.35 |
| 10:35 ET | 200 | 3.35 |
| 10:37 ET | 920 | 3.3405 |
| 10:39 ET | 200 | 3.345 |
| 10:42 ET | 100 | 3.36 |
| 10:44 ET | 4100 | 3.36 |
| 10:46 ET | 100 | 3.39 |
| 10:48 ET | 100 | 3.39 |
| 10:50 ET | 100 | 3.38 |
| 10:51 ET | 2944 | 3.37 |
| 10:53 ET | 200 | 3.3612 |
| 10:55 ET | 1100 | 3.35 |
| 10:57 ET | 1782 | 3.3301 |
| 11:04 ET | 100 | 3.33 |
| 11:06 ET | 400 | 3.3349 |
| 11:08 ET | 750 | 3.34 |
| 11:09 ET | 5432 | 3.36 |
| 11:11 ET | 3352 | 3.3699 |
| 11:13 ET | 1700 | 3.375 |
| 11:15 ET | 103 | 3.3898 |
| 11:18 ET | 200 | 3.39 |
| 11:20 ET | 805 | 3.39 |
| 11:22 ET | 100 | 3.39 |
| 11:24 ET | 12170 | 3.3841 |
| 11:26 ET | 537 | 3.39 |
| 11:27 ET | 100 | 3.39 |
| 11:29 ET | 200 | 3.4 |
| 11:31 ET | 2071 | 3.36 |
| 11:33 ET | 897 | 3.35 |
| 11:38 ET | 1200 | 3.3499 |
| 11:40 ET | 1500 | 3.31 |
| 11:44 ET | 100 | 3.31 |
| 11:51 ET | 9231 | 3.3299 |
| 11:54 ET | 11992 | 3.33 |
| 11:56 ET | 4600 | 3.32 |
| 12:03 ET | 637 | 3.2737 |
| 12:07 ET | 1392 | 3.265 |
| 12:18 ET | 100 | 3.27 |
| 12:20 ET | 200 | 3.27 |
| 12:21 ET | 100 | 3.27 |
| 12:23 ET | 100 | 3.27 |
| 12:25 ET | 300 | 3.27 |
| 12:27 ET | 100 | 3.27 |
| 12:32 ET | 800 | 3.23 |
| 12:36 ET | 2319 | 3.205 |
| 12:39 ET | 500 | 3.2071 |
| 12:41 ET | 300 | 3.2 |
| 12:43 ET | 100 | 3.21 |
| 12:50 ET | 300 | 3.19 |
| 12:59 ET | 100 | 3.19 |
| 01:01 ET | 300 | 3.19 |
| 01:06 ET | 1586 | 3.18 |
| 01:12 ET | 3584 | 3.13 |
| 01:19 ET | 3038 | 3.16 |
| 01:21 ET | 300 | 3.17 |
| 01:24 ET | 900 | 3.18 |
| 01:26 ET | 200 | 3.18 |
| 01:28 ET | 200 | 3.18 |
| 01:30 ET | 2427 | 3.18 |
| 01:33 ET | 161 | 3.172 |
| 01:39 ET | 100 | 3.18 |
| 01:42 ET | 8824 | 3.185 |
| 01:44 ET | 1400 | 3.2 |
| 01:46 ET | 200 | 3.22 |
| 01:48 ET | 200 | 3.23 |
| 01:50 ET | 1926 | 3.22 |
| 01:51 ET | 100 | 3.22 |
| 02:02 ET | 100 | 3.22 |
| 02:04 ET | 700 | 3.23 |
| 02:06 ET | 100 | 3.23 |
| 02:08 ET | 200 | 3.23 |
| 02:09 ET | 100 | 3.23 |
| 02:11 ET | 100 | 3.23 |
| 02:13 ET | 100 | 3.23 |
| 02:18 ET | 100 | 3.23 |
| 02:22 ET | 300 | 3.23 |
| 02:24 ET | 200 | 3.24 |
| 02:26 ET | 100 | 3.25 |
| 02:27 ET | 100 | 3.25 |
May 29, 2024
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences, from 4:36PM ET on Wednesday May 29, 2024 by Dow Jones
4:36PM ET on Wednesday May 29, 2024 by Dow Jones
May 15, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones*DJ Kodiak Sciences 1Q Loss/Shr 82c >KOD, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 167.1M | -0.7x | --- |
Outlook Therapeutics Inc | 165.5M | -0.6x | --- |
Galectin Therapeutics Inc | 169.0M | -3.7x | --- |
X4 Pharmaceuticals Inc | 169.6M | -1.5x | --- |
Atossa Therapeutics Inc | 163.5M | -5.4x | --- |
Rezolute Inc | 161.7M | -3.5x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $167.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.42 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
